The α chain of interleukin 3 receptor (IL-3Rα or CD123), together with the common β (βc)
subunit, forms a high-affinity IL-3R with biological function. In recent years, emerging …

Simple Summary CD123 is overexpressed in multiple hematologic malignancies. Advances
in CD123-targeted therapies over the past decade have positioned this molecule as an …

Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks
immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML …

Leukocyte interleukin-3 receptor α (CD123) is regarded as a marker of leukemia stem cells.
We previously found that CD123 was also highly expressed on CD34+ CD38–cells in …

The increased LSC in MDS has correlation with the progression to AML, which the
mechanism of immune evasion is unclear. Our study showed the expression of CD47 on …

Following the observation of interleukin 3 receptor α chain (IL-3Rα; CD123) upregulation on
leukemia stem cells (LSCs) almost two decades ago, targeted treatment via CD123 …

Simple Summary IL3RA (alpha subunit of the interleukin 3 receptor) is a cell membrane
protein frequently expressed in acute myeloid leukemia (AML) and Hodgkin lymphoma; …

TIM3, as a negative regulator of anti-tumor immunity, is highly expressed on LSCs, but not
on normal HSCs. TIM3 on HSCs in MDS patients has not been clarified. Here, both the …

Low response, treatment-related complications and relapse due to the low sensitivity of
myelodysplastic syndrome (MDS) and leukemia stem cells (LSCs) or pre‑LSCs to arsenic …

Abstract The World Health Organization introduced flow cytometry as an additional criterion
for diagnosis of myelodysplastic syndromes (MDS). Aberrant antigen expression on bone …